THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION

THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION

The review presents the analysis and possible ways of solving the issues of treatment of age related macular degeneration (AMD) based on pharmacogenetic approaches. The AMD problem is relevant because of the growing number of resistant neovascular membranes, an increase in the number of older-age pa...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. A. Bakunina, S. N. Shcherbo, L. N. Kolesnikova
Format:	Article
Language:	Russian
Published:	Real Time Ltd 2018-10-01
Series:	Российский офтальмологический журнал
Subjects:	возрастная макулярная дегенерация фармакогенетика анти-vegf терапия полиморфизмы генов age-related macular degeneration pharmacogenetics anti-vegf therapy genes polymorphisms
Online Access:	https://roj.igb.ru/jour/article/view/156
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery
by: A. A. Kuznetsov, et al.
Published: (2018-10-01)

The Effectiveness of Retinalamin® Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of Age- Related Macular Degeneration
by: V. V. Neroev, et al.
Published: (2018-10-01)

Pathogenetic issues of retinal dystrophies associated with myopia and agerelated macular degeneration
by: I. B. Alekseev, et al.
Published: (2018-10-01)

Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
by: F. A. Bakhritdinova, et al.
Published: (2018-10-01)

The results of a long-term follow up of patients with age-related macular degeneration who received a lutein-containing medication
by: O. V. Zaytseva, et al.
Published: (2018-10-01)

Clinical effectiveness of nutrof total supplement for Dry age-related macular Degeneration
by: E. N. Eskina, et al.
Published: (2018-10-01)

РАЗРАБОТКА РЕЦЕПТУРЫ САХАРНОГО ПЕЧЕНЬЯ ДЛЯ ПОТРЕБИТЕЛЕЙ С ПРЕДРАСПОЛОЖЕННОСТЬЮ К ВОЗРАСТНОЙ МАКУЛЯРНОЙ ДЕГЕНЕРАЦИИ
by: Мария Владимировна Чубарова, et al.
Published: (2022-03-01)

RETRACTED: Efficacy and safety of medicines: the value and opportunities of clinical pharmacology
by: M. V. Zhuravleva, et al.
Published: (2018-02-01)

Functional express testing and self monitoring in the diagnosis and treatment of macular diseases
by: S. O. Milyutkina, et al.
Published: (2018-10-01)

EVALUATION OF SENSITIVITY TO CLOPIDOGREL: THE CURRENT STATE OF THE PROBLEM
by: A. L. Komarov
Published: (2015-12-01)

Pharmacogenetic aspects of substance use disorders
by: A. O. Kibitov
Published: (2018-07-01)

NETWORK APPROACH TO ANALYSIS OF QUANTITATIVE TRAIT LOCI FOR TUMOR NECROSIS FACTOR (TNFα-863, TNFα-308, TNFα-238), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-2578, VEGF+936) AND MATRIX METALLOPROTEINASE (ММР2-1306, ММР3-1171, ММР9-1569) GENES IN AGERELATED MACULAR DEGENERATION
by: A. V. Shevchenko, et al.
Published: (2017-10-01)

Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art
by: R. F. Nasyrova, et al.
Published: (2018-07-01)

Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment
by: L. A. Golota, et al.
Published: (2025-03-01)

Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration
by: Valory Anne S. Vailoces, et al.
Published: (2025-04-01)

Половые различия в биотрансформации лекарственных средств: значение для проведения клинических исследований лекарственных средств
Published: (2020-04-01)

Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration
by: A. N. Kulikov, et al.
Published: (2022-10-01)

Anti-VEGF combined with fufang xueshuangtong versus anti-VEGF monotherapy for wet age-related macular degeneration: A meta-analysis
by: Tingke Xie, et al.
Published: (2025-06-01)

The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
by: Michael Grün, et al.
Published: (2025-04-01)

Tailored Anti-VEGF Therapy with New Generation Optimizations (TANGO) Treatment Regimen for Neovascular Age-Related Macular Degeneration: Rationale, Design, and Simulation Study
by: Subhi Y, et al.
Published: (2025-04-01)

Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity
by: A. N. Kulikov, et al.
Published: (2025-03-01)

Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis
by: Ali Khodor, et al.
Published: (2025-07-01)

ОСОБЛИВОСТІ NF-ΚВ-ОПОСЕРЕДКОВАНОЇ СИГНАЛЬНОЇ ТРАНСДУКЦІЇ ТА РОЗВИТОК СИСТЕМНОГО ЗАПАЛЕННЯ У ПАЦІЄНТІВ ІЗ ЗАХВОРЮВАННЯМИ ВНУТРІШНІХ ОРГАНІВ ВИЗНАЧАЮТЬСЯ МІКРОБНИМ ФАКТОРОМ ТА ІНДИВІДУАЛЬНОЮ РЕАКТИВНІСТЮ ОРГАНІЗМУ (ОГЛЯД ВЛАСНИХ ДОСЛІДЖЕНЬ)
by: L.E. Vesnina, et al.
Published: (2017-03-01)

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study
by: Mekala Shellvarajah, et al.
Published: (2025-04-01)

Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
by: Asim K Ghosh, et al.
Published: (2025-06-01)

Evidence for Whom? A Systematic Review of Eligibility Criteria in RCTs of Anti-VEGF for Neovascular Age-Related Macular Degeneration
by: Andreas Arnold-Vangsted, et al.
Published: (2025-07-01)

THE ROLE OF VASCULAR GROWTH FACTORS IN DIABETIC RETINOPATHY AND MACULAR EDEMA DEVELOPMENT
by: A. G. Iskhakova, et al.
Published: (2018-10-01)

Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study
by: Masayuki Ohnaka, et al.
Published: (2025-05-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Analysis of Clinical Study Results Obtained in Patients with Neovascular Age-Related Macular Degeneration in 2005–2020. Review
by: N. A. Gavrilova, et al.
Published: (2022-04-01)

Knowledge, attitudes, and practices of patients with age-related macular degeneration (AMD) towards Anti-VEGF treatment under one-stop intravitreal injection model
by: Liangzhang Tan, et al.
Published: (2024-11-01)

An Experimental and Clinical Justification for Prolongation of Action of Anti-VEGF Drug in the “Wet” Form Age-related Macular Degeneration by the Introduction in the Back Subtenon Space on the Basis of Viscous Media
by: R. V. Gaybaryan, et al.
Published: (2017-03-01)

The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study
by: V. V. Neroev, et al.
Published: (2023-12-01)

Efficacy and prognostic factors of anti-VEGF treatment for neovascular age-related macular degeneration: An OCTA imaging-based deep learning analysis
by: Shengnan Liu, et al.
Published: (2025-10-01)

New Qualitative Methods for Assessing the “Fluid” in the Retina in Age-Related Macular Degeneration
by: M. V. Budzinskaya, et al.
Published: (2021-07-01)

The effect of a specific vitamin supplement containing L-methylfolate (Ocufolin forte) in patients with neovascular age-related macular degeneration
by: Tatjana Josifova, et al.
Published: (2025-05-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

Сlinical, functional and morphological results of diabetic macular edema antiangiogenic treatment in patients with diabetes mellitus type two
by: L. K. Moshetova, et al.
Published: (2014-07-01)

Vascular Endothelial Growth Factors: Pharmacological aspects and applications in ophthalmic practices
by: Ashok K Dubey, et al.
Published: (2013-10-01)

Vitrectomy for full-thickness macular hole developed during aflibercept treatment for wet age-related macular degeneration
by: Agnieszka Nowosielska
Published: (2024-12-01)